EXTRAHEPATIC CHOLANGIOCARCINOMA
Clinical trials for EXTRAHEPATIC CHOLANGIOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRAHEPATIC CHOLANGIOCARCINOMA trials appear
Sign up with your email to follow new studies for EXTRAHEPATIC CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on biliary cancers: targeted drug plus chemo shows promise
Disease control OngoingThis study tests whether adding the targeted drug binimetinib to standard chemotherapy (mFOLFOX6) can shrink tumors or extend survival in people with advanced biliary tract cancers that have certain genetic changes (MAPK pathway alterations). About 66 participants whose cancer wo…
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New chemo mist targets abdominal cancer with fewer side effects
Disease control TerminatedThis early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug aims to stop bile duct cancer from returning after surgery
Disease control OngoingThis global phase 3 trial is testing whether adding the immunotherapy drug rilvegostomig to standard chemotherapy can help prevent biliary tract cancer from coming back after surgery. About 757 people who had their cancer completely removed will receive either rilvegostomig or a …
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New combo therapy targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests whether combining two drugs—regorafenib (a targeted therapy) and durvalumab (an immunotherapy)—can help people with advanced biliary tract cancer that has stopped responding to chemotherapy. About 40 participants will receive both drugs to see if the combination …
Matched conditions: EXTRAHEPATIC CHOLANGIOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC